Definium Therapeutics Announces New Employee Inducement Grants

Biopharmaceutical company issues stock options and performance share units to four new hires

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Definium Therapeutics, a late-stage clinical biopharmaceutical company developing new therapeutics for psychiatric and neurological disorders, announced the issuance of inducement grants to four newly hired non-executive employees. The grants include options to purchase an aggregate of 134,540 common shares and 34,500 performance share units that will be settled in Definium common shares upon vesting.

Why it matters

The inducement grants are a common practice for biopharmaceutical companies to attract and retain top talent as they work to advance new drug candidates through the clinical trial process. Definium's announcement highlights its efforts to build out its team as it progresses its pipeline of psychedelic-inspired therapeutics.

The details

The options have an exercise price equal to Definium's stock price on the respective grant dates and will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in monthly increments over the next three years. The performance share units will vest on the third anniversary of the grant date, with the actual number of shares earned based on the achievement of certain performance metrics.

  • The grants were issued on February 24, 2026, February 27, 2026 and March 9, 2026.
  • The options and performance share units were approved by Definium's Compensation Committee on February 23, 2026.

The players

Definium Therapeutics

A late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders.

Definium's Compensation Committee

The committee that approved the inducement grants in accordance with Nasdaq rules.

Got photos? Submit your photos here. ›

The takeaway

Definium's announcement of new employee inducement grants highlights the company's efforts to build out its team as it works to advance its pipeline of psychedelic-inspired therapeutics for psychiatric and neurological disorders. The grants, which include stock options and performance share units, are a common practice in the biopharmaceutical industry to attract and retain top talent.